No Association Between PAWR Gene Polymorphisms and Tardive Dyskinesia in Schizophrenia Patients

Overview

Journal Psychiatry Investig

Specialty Psychiatry

Date 2012 Jun 19

PMID 22707972

Citations 1

Authors

Il-Soo Kim

Ho-Kyoung Yoon

Seung-Gul Kang

Young-Min Park

Yong-Ku Kim

Seung-Hyun Kim

Jung-Eun Choi

Leen Kim

Heon-Jeong Lee

Affiliations

Soon will be listed here.

Abstract

Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with the prolonged use of antipsychotic drugs. Since prostate apoptosis response 4 (Par-4) is a key ligand of the dopamine D2 receptor, the Par-4 gene (PAWR) is a good candidate gene to study in the context of TD susceptibility. We examined the association between PAWR gene polymorphisms and TD. Three single nucleotide polymorphisms of PAWR were selected for the analysis: rs7979987, rs4842318, and rs17005769. Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). Genotype/allele-wise and haplotype-wise analyses were performed. There were no significant differences in genotype and allele frequencies between the two groups. Haplotype analysis also did not reveal a difference between the two groups. Within the limitations imposed by the size of the clinical sample, these findings suggest that PAWR gene variants do not significantly contribute to an increased risk of TD.

Citing Articles

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Tsermpini E, Redensek S, Dolzan V Front Pharmacol. 2022; 12:834129.

PMID: 35140610 PMC: 8819690. DOI: 10.3389/fphar.2021.834129.

References

Chen C, Wei F, Koong F, Hsiao K . Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry. 1997; 41(7):827-9. DOI: 10.1016/S0006-3223(96)00543-4. View

Lee T, Seeman P, Tourtellotte W, Farley I, Hornykeiwicz O . Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature. 1978; 274(5674):897-900. DOI: 10.1038/274897a0. View

Park Y, Kang S, Choi J, Kim Y, Kim S, Park J . No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients. Psychiatry Investig. 2011; 8(1):49-54. PMC: 3079185. DOI: 10.4306/pi.2011.8.1.49. View

Liou Y, Chen M, Wang Y, Chen J, Liao D, Bai Y . Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(3):439-40. DOI: 10.1002/ajmg.b.30795. View

Tenback D, van Harten P . Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011; 98:211-30. DOI: 10.1016/B978-0-12-381328-2.00009-2. View

Lee H, Kang S, Paik J, Lee M, Cho B, Park Y . No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol. 2007; 22(8):501-4. DOI: 10.1002/hup.875. View

Jeste D . Tardive dyskinesia in older patients. J Clin Psychiatry. 2000; 61 Suppl 4:27-32. View

Correll C, Leucht S, Kane J . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161(3):414-25. DOI: 10.1176/appi.ajp.161.3.414. View

Faul F, Erdfelder E, Buchner A, Lang A . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4):1149-60. DOI: 10.3758/BRM.41.4.1149. View

10.

Park S, Nguyen M, Fischer A, Luke M, Affar E, Dieffenbach P . Par-4 links dopamine signaling and depression. Cell. 2005; 122(2):275-87. DOI: 10.1016/j.cell.2005.05.031. View

11.

Kang S, Choi J, Park Y, Lee H, Han C, Kim Y . Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology. 2008; 57(1-2):22-5. DOI: 10.1159/000123118. View

12.

Dudbridge F . Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008; 66(2):87-98. PMC: 2386559. DOI: 10.1159/000119108. View

13.

Akyol O, Yanik M, Elyas H, Namli M, Canatan H, Akin H . Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 29(1):123-31. DOI: 10.1016/j.pnpbp.2004.10.014. View

14.

Gerlach J, Hansen L . Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry Suppl. 1992; (17):34-7. View

15.

De Keyser J . Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol. 1991; 14(6):562-5. DOI: 10.1097/00002826-199112000-00009. View

16.

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

17.

Segman R, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M . Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl). 2001; 152(4):408-13. DOI: 10.1007/s002130000521. View

18.

Lee H, Kang S, Choi J, Paik J, Kim Y, Kim S . No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology. 2007; 55(1):47-51. DOI: 10.1159/000103576. View

19.

Tsai H, North K, West S, Poole C . The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2009; 153B(1):57-66. DOI: 10.1002/ajmg.b.30946. View

20.

Kang S, Choi J, An H, Lim S, Lee H, Han C . No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6):1545-8. DOI: 10.1016/j.pnpbp.2008.05.016. View